CKS2 in human cancers: Clinical roles and current perspectives (Review)

You,Hanyu; Lin,Huayue; Zhang,Zhongying

doi:10.3892/mco.2015.501

CKS2 in human cancers: Clinical roles and current perspectives (Review)

Authors:
- Hanyu You
- Huayue Lin
- Zhongying Zhang
View Affiliations

Affiliations: Center for Clinical Laboratory, Xiamen University Affiliated Zhongshan Hospital, Xiamen, Fujian 361000, P.R. China
Published online on: February 4, 2015 https://doi.org/10.3892/mco.2015.501
Pages: 459-463

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cyclin‑dependent kinase subunit 2 (CKS2) is indicated in the processes of cell cycle and cell proliferation. Through these processes, CKS2 is identified as a cancer gene, but its role has not been well reviewed. The aim of the present study was to summarize the clinicopathological significance and the molecular mechanisms of CKS2 in human cancers. Its expression was upregulated in the majority of the types of cancer studied. CKS2 was shown to have a function in cancers of the digestive tract, genital tract, thyroid, nerve and certain other types of cancer. CKS2 can promote progression of certain cancers via positive control of proliferation, invasion and migration. Downregulation of CKS2 induces cancer cell apoptosis. CKS2 can change a multitude of cellular mechanisms in cancer pathogenesis by regulating the gene translation of numerous validated targets, such as p53, CDK1, cyclin A, cyclin B1, caspase‑3 and Bax. In addition, the molecular mechanism that causes aberrant expression of CKS2 was epigenetic modification of miR‑26a and the Y‑box‑binding protein 1 (YB‑1) gene. In conclusion, CKS2 is commonly elevated in cancer, most likely due to its ability to promote cancer cell growth, invasion and migration through regulating certain significant genes. Understanding the mechanisms by which CKS2 is involved with cancer pathogenesis will be useful in the development of tumor therapy for patients with cancer.

View Figures

View References

1	Williams RT, Wu L, Carbonaro-Hall DA, Tolo VT and Hall FL: Identification of a novel cyclin-like protein in human tumor cells. J Biol Chem. 268:8871–8880. 1993.PubMed/NCBI
2	Richardson HE, Stueland CS, Thomas J, Russell P and Reed SI: Human cDNAs encoding homologs of the small p34Cdc28/Cdc2-associated protein of Saccharomyces cerevisiae and Schizosaccharomyces pombe. Genes Dev. 4:1332–1344. 1990. View Article : Google Scholar : PubMed/NCBI
3	Demetrick DJ, Zhang H and Beach DH: Chromosomal mapping of the human genes CKS1 to 8q21 and CKS2 to 9q22. Cytogenet Cell Genet. 73:250–254. 1996. View Article : Google Scholar : PubMed/NCBI
4	Urbanowicz-Kachnowicz I, Baghdassarian N, Nakache C, Gracia D, Mekki Y, Bryon PA and Ffrench M: ckshs expression is linked to cell proliferation in normal and malignant human lymphoid cells. Int J Cancer. 82:98–104. 1999. View Article : Google Scholar : PubMed/NCBI
5	Ganoth D, Bornstein G, Ko TK, Larsen B, Tyers M, Pagano M and Hershko A: The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27. Nat Cell Biol. 3:321–324. 2001. View Article : Google Scholar : PubMed/NCBI
6	Spruck CH, de Miguel MP, Smith AP, Ryan A, Stein P, Schultz RM, Lincoln AJ, Donovan PJ and Reed SI: Requirement of Cks2 for the first metaphase/anaphase transition of mammalian meiosis. Science. 300:647–650. 2003. View Article : Google Scholar : PubMed/NCBI
7	Rother K, Dengl M, Lorenz J, Tschöp K, Kirschner R, Mössner J and Engeland K: Gene expression of cyclin-dependent kinase subunit Cks2 is repressed by the tumor suppressor p53 but not by the related proteins p63 or p73. FEBS Lett. 581:1166–1172. 2007. View Article : Google Scholar : PubMed/NCBI
8	Martinsson-Ahlzén H-S, Liberal V, Grünenfelder B, Chaves SR, Spruck CH and Reed SI: Cyclin-dependent kinase-associated proteins Cks1 and Cks2 are essential during early embryogenesis and for cell cycle progression in somatic cells. Mol Cell Biol. 28:5698–5709. 2008. View Article : Google Scholar : PubMed/NCBI
9	Shen DY, Fang ZX, You P, Liu PG, Wang F, Huang CL, Yao XB, Chen ZX and Zhang ZY: Clinical significance and expression of cyclin kinase subunits 1 and 2 in hepatocellular carcinoma. Liver Int. 30:119–125. 2010. View Article : Google Scholar : PubMed/NCBI
10	Wang JJ, Fang ZX, Ye HM, You P, Cai MJ, Duan HB, Wang F and Zhang ZY: Clinical significance of overexpressed cyclin-dependent kinase subunits 1 and 2 in esophageal carcinoma. Dis Esophagus. 26:729–736. 2013.PubMed/NCBI
11	Kita Y, Nishizono Y, Okumura H, et al: Clinical and biological impact of cyclin-dependent kinase subunit 2 in esophageal squamous cell carcinoma. Oncol Rep. 31:1986–1992. 2014.PubMed/NCBI
12	Tanaka F, Matsuzaki S, Mimori K, Kita Y, Inoue H and Mori M: Clinicopathological and biological significance of CDC28 protein kinase regulatory subunit 2 overexpression in human gastric cancer. Int J Oncol. 39:361–372. 2011.PubMed/NCBI
13	Notterman DA, Alon U, Sierk AJ and Levine AJ: Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res. 61:3124–3130. 2001.PubMed/NCBI
14	Jung Y, Lee S, Choi HS, et al: Clinical validation of colorectal cancer biomarkers identified from bioinformatics analysis of public expression data. Clin Cancer Res. 17:700–709. 2011. View Article : Google Scholar : PubMed/NCBI
15	Yu M, Zhong M and Qiao Z: Expression and clinical significance of cyclin kinase subunit 2 in colorectal cancer. Oncol Lett. 6:777–780. 2013.PubMed/NCBI
16	Li M, Lin Y-M, Hasegawa S, et al: Genes associated with liver metastasis of colon cancer, identified by genome-wide cDNA microarray. Int J Oncol. 24:305–312. 2004.PubMed/NCBI
17	Kawakami K, Enokida H, Tachiwada T, Gotanda T, Tsuneyoshi K, Kubo H, Nishiyama K, Takiguchi M, Nakagawa M and Seki N: Identification of differentially expressed genes in human bladder cancer through genome-wide gene expression profiling. Oncol Rep. 16:521–531. 2006.PubMed/NCBI
18	Chen R, Feng C and Xu Y: Cyclin-dependent kinase-associated protein Cks2 is associated with bladder cancer progression. J Int Med Res. 39:533–540. 2011. View Article : Google Scholar : PubMed/NCBI
19	Scrideli CA, Carlotti CG Jr, Okamoto OK, et al: Gene expression profile analysis of primary glioblastomas and non-neoplastic brain tissue: Identification of potential target genes by oligonucleotide microarray and real-time quantitative PCR. J Neurooncol. 88:281–291. 2008. View Article : Google Scholar : PubMed/NCBI
20	Rickman DS, Bobek MP, Misek DE, Kuick R, Blaivas M, Kurnit DM, Taylor J and Hanash SM: Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res. 61:6885–6891. 2001.PubMed/NCBI
21	Haaber J, Abildgaard N, Knudsen LM, Dahl IM, Lodahl M, Thomassen M, Kerndrup GB and Rasmussen T: Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis. Br J Haematol. 140:25–35. 2008.PubMed/NCBI
22	Williams MD, Zhang L, Elliott DD, Perrier ND, Lozano G, Clayman GL and El-Naggar AK: Differential gene expression profiling of aggressive and nonaggressive follicular carcinomas. Hum Pathol. 42:1213–1220. 2011. View Article : Google Scholar : PubMed/NCBI
23	Lan Y, Zhang Y, Wang J, Lin C, Ittmann MM and Wang F: Aberrant expression of Cks1 and Cks2 contributes to prostate tumorigenesis by promoting proliferation and inhibiting programmed cell death. Int J Cancer. 123:543–551. 2008. View Article : Google Scholar : PubMed/NCBI
24	de Wit NJ, Rijntjes J, Diepstra JH, van Kuppevelt TH, Weidle UH, Ruiter DJ and van Muijen GN: Analysis of differential gene expression in human melanocytic tumour lesions by custom made oligonucleotide arrays. Br J Cancer. 92:2249–2261. 2005. View Article : Google Scholar : PubMed/NCBI
25	Wong YF, Cheung TH, Tsao GS, et al: Genome-wide gene expression profiling of cervical cancer in Hong Kong women by oligonucleotide microarray. Int J Cancer. 118:2461–2469. 2006. View Article : Google Scholar : PubMed/NCBI
26	Ni RS, Shen X, Qian X, Yu C, Wu H and Gao X: Detection of differentially expressed genes and association with clinicopathological features in laryngeal squamous cell carcinoma. Oncol Lett. 4:1354–1360. 2012.PubMed/NCBI
27	Menghi F, Orzan FN, Eoli M, et al: DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence. Oncologist. 16:1440–1450. 2011. View Article : Google Scholar : PubMed/NCBI
28	Kang MA, Kim JT, Kim JH, Kim SY, Kim YH, Yeom YI, Lee Y and Lee HG: Upregulation of the cycline kinase subunit CKS2 increases cell proliferation rate in gastric cancer. J Cancer Res Clin Oncol. 135:761–769. 2009. View Article : Google Scholar : PubMed/NCBI
29	Shen DY, Zhan YH, Wang QM, Rui G and Zhang ZM: Oncogenic potential of cyclin kinase subunit-2 in cholangiocarcinoma. Liver Int. 33:137–148. 2013. View Article : Google Scholar : PubMed/NCBI
30	Gendreau KM and Whalen GF: What can we learn from the phenomenon of preferential lymph node metastasis in carcinoma? J Surg Oncol. 70:199–204. 1999. View Article : Google Scholar : PubMed/NCBI
31	Lyng H, Brøvig RS, Svendsrud DH, Holm R, Kaalhus O, Knutstad K, Oksefjell H, Sundfør K, Kristensen GB and Stokke T: Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer. BMC Genomics. 7:2682006. View Article : Google Scholar : PubMed/NCBI
32	Lin HM, Chatterjee A, Lin YH, Anjomshoaa A, Fukuzawa R, McCall JL and Reeve AE: Genome wide expression profiling identifies genes associated with colorectal liver metastasis. Oncol Rep. 17:1541–1549. 2007.PubMed/NCBI
33	Dorée M and Hunt T: From Cdc2 to Cdk1: when did the cell cycle kinase join its cyclin partner? J Cell Sci. 115:2461–2464. 2002.PubMed/NCBI
34	Vassilev LT, Tovar C, Chen S, Knezevic D, Zhao X, Sun H, Heimbrook DC and Chen L: Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc Natl Acad Sci USA. 103:10660–10665. 2006. View Article : Google Scholar : PubMed/NCBI
35	LV M, Zhang X, Li M, Chen Q, Ye M, Liang W, Ding L, Cai H, Fu D and Lv Z: miR-26a and its target CKS2 modulate cell growth and tumorigenesis of papillary thyroid carcinoma. PLoS ONE. 8:e675912013. View Article : Google Scholar : PubMed/NCBI
36	Kohno K, Izumi H, Uchiumi T, Ashizuka M and Kuwano M: The pleiotropic functions of the Y-box-binding protein, YB-1. BioEssays. 25:691–698. 2003. View Article : Google Scholar : PubMed/NCBI
37	Yu YN, Yip GW, Tan PH, Thike AA, Matsumoto K, Tsujimoto M and Bay BH: Y-box binding protein 1 is up-regulated in proliferative breast cancer and its inhibition deregulates the cell cycle. Int J Oncol. 37:483–492. 2010.PubMed/NCBI